Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck faces significant challenges, including increased competition and regulatory scrutiny for Keytruda. Keytruda is facing potential threats from competitors like Summit Therapeutics ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

MOSCOW. Aug 26 (Interfax) - Ukraine and India have signed an agreement on cooperation in agriculture and food industry, Ukrainian media reported, citing the Agrarian Policy and Food Ministry's press ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...

MLB Tonight discusses Ketel Marte's ankle injury sending him to the IL and how the D-backs' push for the postseason changes without him ...

To give our readers a chance to experience all that our new website has to offer, we have made all content freely avaiable, through October 1, 2018. During this time, print and digital subscribers ...

Audi has released a new special edition version of the TT. Limited to 999 examples globally, 150 of which are coming to the UK, the “TT 20 Years” edition will be on sale in early 2019. UK ...